title: Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
abstract: JNJ-Q2, a fluorinated 4-quinolone, was very active against both methicillin-susceptible Staphylococcus aureus (n = 42; MIC(50/90), 0.008/0.12 μg/mL) and methicillin-resistant S. aureus (n = 69; MIC(50/90), 0.12/0.12 μg/mL) obtained from patients with acute bacterial skin and skin-structure infection (ABSSSI). Overall moxifloxacin and levofloxacin resistance rates were 31.5% and 46.9%, respectively. These favorable results support the continued clinical development of JNJ-Q2 to treat ABSSSI.
authors: JMI Laboratories, North Liberty, IA 52317, USA.
authors: David J
authors: DJ
authors: Farrell
authors: Lisa L
authors: LL
authors: Turner
authors: Mariana
authors: M
authors: Castanheira
authors: Ronald N
authors: RN
authors: Jones
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D013207:Staphylococcal Skin Infections / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification
chemical_list: C550935:7-(3-(2-amino-1-fluoroethylidene)-1-piperidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid; D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D064704:Levofloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin